EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The primary purpose is to determine the changes in gene expression induced by IFNb-1a (Rebif)
and atorvastatin (Lipitor) combination therapy in patients with an isolated clinical syndrome
suggestive of multiple sclerosis (MS), to identify markers of therapeutic response, and to
predict patients' clinical response based on their in vitro response to this combination
therapy measured by the gene expression levels in activated peripheral blood mononuclear
cells (PBMCs).